Skip to Content

Canagliflozin Beneficial Even for Advanced Kidney Disease

MONDAY, Nov. 30, 2020 -- Treatment with the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduces the rate of kidney disease progression among participants with an estimated glomerular filtration rate (eGRF) <30 mL/min/1.73 m2, according to a study published online Nov. 19 in the Clinical Journal of the American Society of Nephrology.

George Bakris, M.D., from the University of Chicago Medicine, and colleagues conducted a post-hoc analysis to examine the impact of canagliflozin among CREDENCE trial participants with eGRF <30 mL/min/1.73 m2 at randomization. Data were included for 174 of 4,401 participants (4 percent) with eGFR <30 mL/min/1.73 m2.

The researchers observed a 66 percent difference in the mean rate of eGFR decline from weeks 3 to 130 with canagliflozin versus placebo (mean slopes, –1.30 versus –3.83 mL/min/1.73 m2/year). For those with <30 and ≥30 mL/min/1.73 m2, the effects of canagliflozin were consistent on kidney, cardiovascular, and mortality outcomes (all P interaction > 0.20). The estimate for kidney failure was similar for participants with eGFR <30 and ≥30 mL/min/1.73 m2 (P interaction = 0.80). The rate of kidney-related adverse events or acute kidney injury associated with canagliflozin was not imbalanced between participants with eGFR <30 and ≥30 mL/min/1.73 m2 (P interaction > 0.12).

"These results support the use and continuation of SGLT2 inhibitor treatment even in patients with eGFR <30 mL/min/1.73 m2 until the commencement of maintenance dialysis or receipt of a kidney transplant, and clinicians should consider this when discussing treatment options for patients with low eGFR," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Janssen Research & Development, which sponsored the CREDENCE trial and developed canagliflozin in collaboration with Mitsubishi Tanabe Pharma Corporation.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Posted: November 2020

Read this next

Stopping RAS Inhibitors May Worsen Outcomes in CKD

FRIDAY, Jan. 15, 2021 -- The decision to stop renin-angiotensin system (RAS) inhibitor therapy in patients with advanced chronic kidney disease (CKD) should take into account both...

Many Dialysis Patients Report Proficiency in Mobile Health

FRIDAY, Jan. 8, 2021 -- Most dialysis patients have access to internet-capable devices and report intermediate or advanced mobile health proficiency, according to a study...

eGFR Variability Linked to All-Cause Mortality Risk

WEDNESDAY, Jan. 6, 2021 -- Among people with hypertension who are at high risk for cardiovascular disease (CVD), greater estimated glomerular filtration rate (eGFR) variability is...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.